|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study sought to examine whether conversion from calcineurin inhibitor (CNI)-based to SRL-based IS was associated with decreased risk of malignancy post-HT.
|
31146812 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Those changes may impact clinical immunosuppression with evidences suggesting age-specific efficacies of some (CNI and mammalian target of rapamycin inhibitors) but not necessarily all immunosuppressants.
|
31107822 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no a significant difference in the frequency of CD3<sup>+</sup>CD8<sup>+</sup> CD28<sup>-</sup> Tregs between two different calcineurin inhibitor (CNI)-based immunosuppression protocols.
|
30597187 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the 12-month, open-label MANDELA study, patients were randomized at month 6 after heart transplantation to (i) convert to calcineurin inhibitor (CNI)-free immunosuppression with everolimus (EVR), mycophenolic acid and steroids (CNI-free, n=71), or to (ii) continue reduced-exposure CNI, with EVR and steroids (EVR/redCNI, n=74).
|
30884079 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
As conversion from calcineurin inhibitor (CNI) to sirolimus (SRL), an mTOR-inhibitor (mTOR-I), has been shown to enhance immunoregulatory profiles in liver transplant recipients (LTR), mTOR-I therapy might allow for increased success with immunosuppression withdrawal.
|
31721246 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eighty-two patients (19 CNI free, 34 CNI low-dose and 29 standard-dose CNI immunosuppression) 10 years after liver transplantation and 32 adjusted healthy controls underwent nonlocalised brain phosphorus magnetic resonance spectroscopy (MRS) and single voxel proton MRS in the parietal white matter to estimate brain metabolite contents.
|
31006881 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further supporting an important role for T cells in controlling anti-LG3 levels, we found that human renal transplant recipients show a significant decrease in anti-LG3 titers upon the initiation of CNI-based immunosuppression.
|
30129231 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early everolimus-based quadruple low CNI immunosuppression may improve renal function without compromising efficacy or safety.
|
30615259 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective cohort study, we assessed the efficacy and safety of treating patients at high cardiovascular risk with Belatacept (<i>n</i> = 34, for 1194 observation months) when compared to a matched control group of 150 individuals under CNI immunosuppression (for 7309 months of observation).
|
31382583 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunosuppression was CNI-based, with a mean dose increase of 48.3% (tacrolimus) and 26.5% (cyclosporine), without rejection.
|
29480943 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Benefits and risks of under-immunosuppression must be carefully evaluated before deciding on CNI minimization.
|
30219043 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Costimulation blockade, specifically CD28/B7 inhibition with belatacept, has emerged as a clinical replacement for CNI-based immunosuppression in kidney transplantation.
|
29723921 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the differential effects of SRL-based and calcineurin inhibitor (CNI)-based immunosuppression on CAV progression and clinical outcomes in HT recipients.
|
30174165 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
A cohort of 402 patients who underwent HT and were either treated with CNI alone (n = 134) or converted from CNI to SRL (n = 268) as primary immunosuppression was analyzed.
|
29420960 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective, observational study we investigated 20 patients (10 females, 10 males) who were switched from a CNI (tacrolimus) to a belatacept-based immunosuppression because of CNI intolerance or marginal transplant function.Patient follow-up was 12 months.
|
28540602 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolonged exposure to CNI immunosuppression medications significantly increases the risk for ESRD among HTx recipients.
|
27642059 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data of 80 HTX patients after change to mTOR/CNI-based immunosuppression were retrospectively analyzed.
|
28652705 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we describe cognitive function in a cohort of HTx recipients and subsequently compare cognitive function between subjects on either everolimus- or calcineurin inhibitor (CNI)-based immunosuppression.
|
28185318 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of EVR with early CNI withdrawal after HTx on albuminuria and renal function seem dissociated; hence, the clinical significance of albuminuria in this setting is uncertain and should not necessarily rule out EVR-based immunosuppression.
|
28230646 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression.
|
27888551 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, early introduction of everolimus at an adequate exposure level with gradual calcineurin inhibitor (CNI) withdrawal after liver transplantation, supported by induction therapy and mycophenolic acid, is associated with a significant renal benefit versus CNI-based immunosuppression but more frequent BPAR.
|
28133906 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
They were treated with standard immunosuppression: calcineurin inhibitor (CNI)+azathioprine (AZA)+steroids (n=28) or with CNI+mycophenolate mofetil (MMF)+steroids (n=11) or with CNI+steroids (n=12).
|
17161354 |
2006 |